Nemolizumab for LS

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT07704775
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Lichen Sclerosus of Vulva

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nemolizumab 30 mg — BIOLOGICAL
    Participants will be treated with subcutaneous (SC) nemolizumab injections at doses determined by patient weight.

Study Details

Patients ≥ 18 years of age with Lichen sclerosis (LS)

Key Dates

First listed
Jul 15, 2026
Start date
Sep 1, 2026
Status verified
Jul 2026
Primary completion
Sep 1, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    Participants will be treated with subcutaneous (SC) nemolizumab injections

Primary Outcome Measure

A ≥ 4-point improvement in Itch NRS score [ Time Frame: Baseline to Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas Southwestern Medical CenterDallasTexas75390-

Find similar trials in Dallas, TX

By research site
University of Texas Southwestern Medical Center· Dallas, TX

Related Studies